Brentuximab Vedotin + Rituximab as Frontline Therapy for Pts w/ CD30+ and/or EBV+ Lymphomas
Status:
Terminated
Trial end date:
2018-12-31
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate how safe and effective the combination of two
different drugs (brentuximab vedotin and rituximab) is in patients with certain types of
lymphoma. This study is for patients who have a type of lymphoma that expresses a tumor
marker called CD30 and/or a type that is associated with the Epstein-Barr virus (EBV-related
lymphoma) and who have not yet received any treatment for their cancer, except for
dose-reduction or discontinuation (stoppage) of medications used to prevent rejection of
transplanted organs (for those patients who have undergone transplantation). This study is
investigating the combination of brentuximab vedotin and rituximab as a first treatment for
lymphoma patients